TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* AML patients in first relapse or refractory after all prior therapy~* Presence of the FLT3-ITD activating mutation in bone marrow or peripheral blood~* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 2~Exclusion Criteria:~* Diagnosis of acute promyelocytic leukemia~* AML secondary to prior chemotherapy for other neoplasms.~* Persistent, clinically significant \> Grade 1 non-hematologic toxicity from prior AML therapy~* Prior treatment with a FLT3 targeted therapy~* Active infection not well controlled by antibacterial, antifungal and/or antiviral therapy

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Initial dose 30 mg/day quizartinib (Type: EXPERIMENTAL): Participants who received an initial dose of 30 mg/day of quizartinib and, if no QT prolongation, the dose escalated to 60 mg/day at Day 15.
- Initial dose 20 mg/day quizartinib (Type: EXPERIMENTAL): Participants who received a CYP3A4 strong inhibitor received an initial dose of 20 mg/day of quizartinib and, if no QT prolongation, the dose escalated to 30 mg/day at Day 15.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mechanisms of Preventing Antibiotic-Associated Diarrhea and the Role for Probiotics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Has the ability to read, speak, and write in English~2. Has refrigerator (for proper storage of the study yogurt)~3. Has reliable telephone access~4. Is between ages of 18-65 years~5. Agree to refrain from eating yogurts, yogurt drinks, and other foods specified in the provided What Not to Eat list~6. Agree to collect stool samples and participate in follow-up calls as specified~Exclusion Criteria:~1. Diabetes or asthma that requires medication~2. Allergy to strawberry~3. Active diarrhea (three or more loose stools per day for two consecutive days)~4. Any gastrointestinal (or digestive tract) medications, i.e. medicines for irritable bowel syndrome, gastroesophageal (acid) reflux disease, inflammatory bowel disease, etc.~5. History of heart disease, including valvulopathies or cardiac surgery, any implantable device or prosthetic~6. History of gastrointestinal surgery or disease~7. Lactose intolerance that prevents participant from eating yogurt~8. Allergy to milk-protein~9. Allergy to any component of the product or the yogurt vehicle~10. Allergy to penicillin or cephalosporin class antibiotics~11. Allergy to any of the following medications: a) Penicillin; b) Erythromycin; c) Tetracycline; d) Trimethoprim; e) Ciprofloxacin~12. Women who are breastfeeding, pregnant, or planning to become pregnant during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Control (Type: PLACEBO_COMPARATOR): Yogurt without Bifidobacterium animalis subsp. lactis BB-12 (BB-12) and Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
- BB-12 (Type: EXPERIMENTAL): Bifidobacterium animalis subsp. lactis BB-12 (BB-12)-supplemented yogurt and Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Enhanced Problem-Solving Training

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* OEF/OIF/OND Veteran~* history of mild Traumatic Brain Injury and persistent post-concussion-like symptoms of 3 months~* Brief Symptom Inventory-18 (BSI-18) T-score \> 53~* enrolled in VA primary care (appointment within last 12 months)~* English speaking, able to read and write, and able to comprehend study materials~Exclusion Criteria:~* prior, current, or pending enrollment in a cognitive rehabilitation program or other specific TBI intervention program~* moderate to severe TBI or other major neurocognitive disorder~* psychotic disorder, e.g.: schizophrenia spectrum disorder, delusional disorder, schizotypal personality disorder, bipolar or depressive disorder with psychotic features~* acute suicidal ideation~* inpatient psychiatric hospitalization within the past 12 months~* any other illness or condition that would preclude or predictably influence ability to travel to, or engage in, study visits, as determined by the study team

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- E-PST (randomized) (Type: EXPERIMENTAL): Enhanced Problem-Solving Training (E-PST) arm. E-PST is a combined treatment that is comprised of brief problem-solving training and compensatory cognitive skills training. Randomized participants were assigned 1:1 to E-PST or HLM.
- Control (randomized) (Type: ACTIVE_COMPARATOR): Healthy Living Messages (Control) arm. Healthy Living Messages (HLM) are primary care-congruent messages that consist of simple advice regarding general health behaviors and preventive care. Randomized participants were assigned 1:1 to E-PST or HLM.
- E-PST (non-randomized) (Type: OTHER): Enhanced Problem-Solving Training (E-PST) arm. E-PST is a combined treatment that is comprised of brief problem-solving training and compensatory cognitive skills training. Non-randomized participants were assigned to E-PST only.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate the Efficacy and Safety of rhuMAb Beta7 in Patients With Moderate to Severe Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of moderate to severe ulcerative colitis outpatient~* Disease duration at time of screening of \>/= 12 weeks~Exclusion Criteria:~* Extensive colonic resection or subtotal or total colectomy~* Presence of an ileostomy or colostomy~* Moderate to severe anemia~* A history or evidence of colonic mucosal dysplasia~* Pregnant or lactating~* Significant uncontrolled co-morbidity, such as neurological, cardiac, pulmonary, renal, hepatic, endocrine, or gastrointestinal (GI) disorders~* Significant screening ECG abnormalities, including evidence of acute myocardial infarction, complete left bundle branch block, second-degree heart block, or complete heart block~* Poorly controlled diabetes~* Impaired renal function~* Impaired hepatic function in the absence of a diagnosis of primary sclerosing cholangitis~* Positive tests for antibodies indicating active or prior infection with HIV or hepatitis B (HBV) or C (HCV)~* Positive screening test for latent mycobacterium tuberculosis (TB) infection~* Demyelinating disease~* Received any investigational treatment within 12 weeks prior to initiation of study treatment~* Previous exposure to rhuMAb Beta7

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- rhuMAb Beta7 (Type: EXPERIMENTAL): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial Comparing Atropine to Atropine Plus a Plano Lens for the Sound Eye for Amblyopia in Children 3 to <7 Years Old

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be 3 to less than 7 years old with amblyopia associated with strabismus, anisometropia, or both.~* Visual acuity in the amblyopic eye must be between 20/40 and 20/400 inclusive, visual acuity in the sound eye 20/40 or better and inter-eye acuity difference \> 3 logMAR lines.~* Spectacles, if needed, must be worn for at least 16 weeks or until visual acuity documented to be stable.~Exclusion Criteria:~* Atropine treatment within 6 months of enrollment and other amblyopia treatment of any type (other than normal spectacle lenses) used within one month of enrollment~* No myopia in amblyopic eye

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- Atropine (Type: ACTIVE_COMPARATOR): Atropine 1% once each weekend day in the sound eye
- Atropine plus plano (Type: ACTIVE_COMPARATOR): Atropine 1% once each weekend day in the sound eye plus a plano lens for the sound eye

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Removal of Doravirine by Hemodialysis in HIV-Infected Patients With End-stage Renal Disease (ESRD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females\* aging ≥ 18 years.~2. Documented HIV infection).~3. Stable antiretroviral treatment for at least 2 weeks prior to enrolment.~4. Optimal adherence to antiretroviral treatment, defined as less than 2 missed doses within the previousweek.~5. End-stage renal disease in renal replacement therapy with periodic hemodialysis.~6. Agree with the study procedures and signature of the informed consent. \*Women of childbearing potential must have a negative pregnancy test prior to randomization into the study and commitment to useat least one of these birth control methods: male or female condom with or without spermicide, cap, diaphragm or sponge with orwithout spermicide, intrauterine device, bilateral tubal occlusion, vasectomized partner, sexual abstinence during the study. Condomuse is considered as an additional method of contraception only and cannot be the only method of contraception used as not beenconsidered an effective method by the Clinical Trial Facilitation Group (CTFG) guidelines.~Based on ICH, M3 (R2) 2009 a woman is considered of childbearing potential: fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilization methods include tubal ligation, hysterectomy, bilateral oophorectomy.~Exclusion Criteria:~1. Evidence or clinical suspicion that the patient will not be able to comply with the study protocol.~2. Hypersensitivity to doravirine~3. Concomitant therapy within the previous 4 weeks with any of the following drugs:~   * Anticonvulsants: carbamazepine, oxcarbazepine, phenobarbital, phenytoin~  * Androgen receptor inhibitor: enzalutamide~  * Antimycobacterials: rifampin, rifapentine~  * Cytotoxic agent: mitotane~  * St. John's wort (Hypericum perforatum)~4. Females who are pregnant or breastfeeding.~5. ALT and/ or AST ≥ 4 times the upper limit of normal (ULN) at screening.~6. Hemoglobin \< 7,5 g/dL at screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Experimental group (Type: EXPERIMENTAL): Doravirine (Pifeltro, MSD) will be added to participant's cART (100 mg once daily) for 5 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Quality of Life After Interventional Thyroid Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of a thyroid disease requiring radioiodine treatment~* Clinical diagnosis of a thyroid disease requiring follow-up but no ablative treatment (controls)~* Clinical diagnosis of a thyroid disease requiring surgery stopped recruiting~Exclusion Criteria:~* paediatric patients~* interfering comorbidity~* non-thyroidal illness~* pregnancy~* psychiatric disease~* severe psychological disorder~* lack of consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- surgery (withdrawn, not continuing recruiting) (Type: None): thyroid patients receiving replacement treatment with levothyroxine (LT4) after thyroidectomy
- radioiodine (Type: None): thyroid patients receiving replacement treatment with levothyroxine (LT4) following radioiodine treatment
- control (Type: None): thyroid patients followed without surgery or radioiodine treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TachoSil® Versus Standard Haemostatic Treatment of Haemorrhage in Cardiovascular Surgery (TC-023-IM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~All inclusion criteria must be answered yes for a subject to participate in the trial.~At Screening:~1. Has the subject given informed consent according to local requirements before any trial related activities? A trial related activity is any procedure that would not have been performed during the routine management of the subject. In this trial the screening is the first trial related activity.~2. For female subjects of childbearing potential: Is the pregnancy test at screening negative?~3. Does the female subject of childbearing potential use adequate contraception (contraceptive pill, contraceptive injection, contraceptive implant or intrauterine device)?~4. Is the subject ≥ 18 years of age?~5. Is the following planned: An elective surgery on the heart, the ascending aorta or arch, requiring cardiopulmonary bypass procedure?~   Intra operative (after primary haemostatic treatment):~6. Is bleeding from the heart muscle, the pericardium, a major vessel or a vascular bed that requires supportive haemostatic treatment present?~7. Has the area with the most problematic haemorrhage (target area) been identified? (please note that this must be done before randomisation).~8. Is it possible to compress the randomised treatment (TachoSil® or control fleece material) for 3 minutes?~Exclusion Criteria:~All exclusion criteria must be answered no for a subject to participate in the trial.~At Screening:~1. Has the subject participated in any other trial with an investigational drug or device within 30 days before inclusion in this trial?~2. Does the subject participate in a clinical trial concomitantly with the present trial?~3. Is the subject undergoing an emergency operation?~4. Has the subject a history of allergic reactions after application of human fibrinogen, human thrombin and/or collagen of any origin?~5. Is the subject suffering from known coagulopathy?~6. Is the subject currently participating or has the subject previously participated in the TC-023-IM trial?~7. Is the female subject pregnant or breast feeding?~   Intra operative (after primary haemostatic treatment):~8. Has liquid fibrin sealant/glue or TachoSil® been applied?~9. Has the following occurred: Disseminated intravascular coagulation (DIC), i.e. micro vascular bleeding?

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TachoSil® (Type: ACTIVE_COMPARATOR): None
- Standard Treatment (Type: ACTIVE_COMPARATOR): Standard Treatment of haemorrhage in cardiovascular surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Outpatient Pump Shutoff Pilot Feasibility and Efficacy Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of type 1 diabetes and using daily insulin therapy for at least one year and an insulin infusion pump for at least 6 months~* Age \>/= 15.0 - 45 years~* HbA1c \</= 8.0%~* Availability of internet access for periodic upload of study data~Exclusion Criteria:~* Diabetic ketoacidosis in the past 3 months~* Hypoglycemic seizure or loss of consciousness in the past 6 months~* History of seizure disorder (except for hypoglycemic seizure)~* History of any heart disease including coronary artery disease, heart failure, or arrhythmiasCoronary artery disease or heart failure~* Cystic fibrosis~* Current use of oral/inhaled glucocorticoids, beta-blockers or other medications, which in the judgment of the investigator would be a contraindication to participation in the study.~* History of ongoing renal disease (other than microalbuminuria), or liver disease (Creatinine \> 1.5 mg/dL (0.08 mmol/L))~* Medical or psychiatric condition that in the judgment of the investigator might interfere with the completion of the protocol such as:~  * Inpatient psychiatric treatment in the past 6 months~ * Uncontrolled adrenal disorder~ * Abuse of alcohol~* Pregnancy~* Liver disease as defined by an ALT greater than 3 times the upper limit of normal

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Pump suspension algorithm (Type: ACTIVE_COMPARATOR): The study laptop will be running actively during the night and suspending the patient's pump if the algorithm predicts hypoglycemia based on the patient's continuous glucose sensor trend.
- Standard of Care (Type: NO_INTERVENTION): The control algorithm will run passively and not recommend control the patient's pump.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1/2 Study of AEB1102 in Patients With Arginase I Deficiency

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Documented diagnosis of Arginase I deficiency~* Adequate organ function: Hgb ≥ 10 g/dL, ANC ≥ 1.5 x 109/L, plt count ≥ 100,000/µL; liver transaminase levels ≤ 2.5x ULN, total bilirubin ≤ 2.0 mg/dL; serum creatinine \<1.5 x ULN~* If female and of child-bearing potential, has a negative serum pregnancy test within 7 days before enrollment~* If a sexually active (male or female), must be surgically sterile, post-menopausal (female), or must agree to use a physician-approved method of birth control during the study and for a minimum of 30 days after the last study drug administration~* Patient or legal guardian is able and willing to provide written informed consent and to comply with all requirements of study participation (including all study procedures and continuation of prescribed diet without modification) prior to any screening procedures~Exclusion Criteria:~* Transfusion of ≥ 2 u RBC within 60 days~* Active infection requiring systemic treatment~* Known infection with HIV, Hep B or Hep C~* Severe hyperammonemia requiring hospitalization within 14 days. Had more than one episode of hyperammonemia requiring hospitalization within the 30 days prior to enrollment.~* Current uncontrolled hyperammonemia~* Has a history of hypersensitivity to PEG or any other component of the AEB1102 (Co-ArgI-PEG) formulation~* If female, is lactating or breast feeding~PART 2 INCLUSION CRITERION:~1. Did not experience any safety or tolerability event in Part 1 which would preclude continued participation and dosing of AEB1102

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AEB1102 (Type: EXPERIMENTAL): AEB1102, modified human Arginase I administered IV Part 1 Each patient may receive up to 7 doses given up to every other week over a maximum of 14 weeks.~Part 2 Each patient will receive up to 8 weeks of repeat-dose therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact in Off-spring of Mothers After Perinatal Daily Intake of a Probiotic

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All pregnant women understanding Norwegian language and who has signed an informed consent form, can be included.~* Inclusion must take place before week 36 in the pregnancy.~* The woman must plan to breast-feed the first 4 months after birth.~* She must live in Trondheim.~Exclusion Criteria:~* Not being able to fill in the questionnaire in Norwegian language~* Lactose intolerance~* Consumption of probiotics earlier in the pregnancy.~* Intention to move from Trondheim in the next 25 months.~* Pregnant women in risk of eclampsia, or other serious disease that can influence beast-feeding or care for the child.

- Gender: ALL
- Minimum Age: 30 Weeks
- Maximum Age: 36 Weeks
- Healthy Volunteers: t

Study Arms:
- probiotic (Type: EXPERIMENTAL): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete